Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

69 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Conditioning with treosulfan and fludarabine followed by allogeneic hematopoietic cell transplantation for high-risk hematologic malignancies.
Nemecek ER, Guthrie KA, Sorror ML, Wood BL, Doney KC, Hilger RA, Scott BL, Kovacsovics TJ, Maziarz RT, Woolfrey AE, Bedalov A, Sanders JE, Pagel JM, Sickle EJ, Witherspoon R, Flowers ME, Appelbaum FR, Deeg HJ. Nemecek ER, et al. Among authors: kovacsovics tj. Biol Blood Marrow Transplant. 2011 Mar;17(3):341-50. doi: 10.1016/j.bbmt.2010.05.007. Epub 2010 May 26. Biol Blood Marrow Transplant. 2011. PMID: 20685259 Free PMC article. Clinical Trial.
Phase 2 trial of CPX-351, a fixed 5:1 molar ratio of cytarabine/daunorubicin, vs cytarabine/daunorubicin in older adults with untreated AML.
Lancet JE, Cortes JE, Hogge DE, Tallman MS, Kovacsovics TJ, Damon LE, Komrokji R, Solomon SR, Kolitz JE, Cooper M, Yeager AM, Louie AC, Feldman EJ. Lancet JE, et al. Among authors: kovacsovics tj. Blood. 2014 May 22;123(21):3239-46. doi: 10.1182/blood-2013-12-540971. Epub 2014 Mar 31. Blood. 2014. PMID: 24687088 Free PMC article. Clinical Trial.
Nonmyeloablative allogeneic hematopoietic stem cell transplant for the treatment of patients with hematologic malignancies using busulfan, fludarabine, and total body irradiation conditioning is effective in an elderly and infirm population.
Brammer JE, Stentz A, Gajewski J, Curtin P, Hayes-Lattin B, Kovacsovics T, Leis JF, Meyers G, Nemecek E, Subbiah N, Frires R, Palmbach G, Avraham GP, Slater S, Maziarz RT. Brammer JE, et al. Biol Blood Marrow Transplant. 2015 Jan;21(1):89-96. doi: 10.1016/j.bbmt.2014.09.024. Epub 2014 Oct 16. Biol Blood Marrow Transplant. 2015. PMID: 25445641 Free article. Clinical Trial.
A phase 1 trial of vadastuximab talirine combined with hypomethylating agents in patients with CD33-positive AML.
Fathi AT, Erba HP, Lancet JE, Stein EM, Ravandi F, Faderl S, Walter RB, Advani AS, DeAngelo DJ, Kovacsovics TJ, Jillella A, Bixby D, Levy MY, O'Meara MM, Ho PA, Voellinger J, Stein AS. Fathi AT, et al. Among authors: kovacsovics tj. Blood. 2018 Sep 13;132(11):1125-1133. doi: 10.1182/blood-2018-03-841171. Epub 2018 Jul 25. Blood. 2018. PMID: 30045838 Free PMC article. Clinical Trial.
69 results